Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13283265 | 0.81 | HTT (0.69) | TSHRMAP4K4ALDH1A1HSD17B10LMNA | |
| SCHEMBL2622072 | 0.80 | HTT (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL8297788 | 0.80 | HTT (0.64) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL9128540 | 0.79 | EGFR (0.64) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL28475211 | 0.78 | CD38 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL1585784 | 0.78 | HTT (0.47) | CYP1A2CYP2D6CLK4MAP4K4ALDH1A1 | |
| SCHEMBL28469603 | 0.78 | MAPK1 (0.65) | ALDH1A1LMNAMAPK1HPGDKDM4E | |
| SCHEMBL15587953 | 0.77 | CD38 (0.64) | CYP1A2CYP3A4CLK4MAP4K4ALDH1A1 | |
| SCHEMBL1584864 | 0.77 | IRAK4 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL1192879 | 0.77 | EGFR (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-1101386-C | Trisubstd phenyl derivs | NOVARTIS AG (CH) | 2003-02-12 | — | — | CN | disclosed |
| EP-0815087-B1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| US-5990116-A | USE IN PREVENTION OR TREATMENT OF INFLAMMATORY AND PROLIFERATIVE SKIN DISEASES AND CANCER; COMPOUNDS SUCH AS 6-(2-(2,5-DIMETHOXYPHENYL)ETHYL)-4-ETHYL-QUINAZOLINE | NOVARTIS AG (CH) | 1999-11-23 | — | — | US | disclosed |
| CN-1183774-A | Trisubstd phenyl derivs | CIBA GEIGY AG (CH) | 1998-06-03 | — | — | CN | disclosed |
| EP-0815087-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028430-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | CYP1A2 2360/4885CYP3A4 1482/4885CYP2D6 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.